The Centers for Disease Control and Prevention on Friday opened Pfizer-BioNTech booster shots to millions of Americans, recommending third doses for older adults and several medically vulnerable groups while also allowing them for people whose jobs or institutional settings place them at increased risk of exposure.

The final CDC guidance recommends a booster at least six months after the Pfizer primary series for people 65 and older and residents of long-term-care facilities. It also says adults ages 50 to 64 with underlying medical conditions should receive a booster, while adults 18 to 49 with underlying conditions may receive one after weighing individual benefits and risks.

CDC Director Rochelle Walensky went one step beyond the agency’s Advisory Committee on Immunization Practices by also recommending that adults ages 18 to 64 at increased risk because of occupational or institutional exposure may receive a booster. That category can include healthcare workers, teachers, grocery workers and people in prisons or homeless shelters.

The CDC decision follows the Food and Drug Administration’s Wednesday authorization of a Pfizer booster for three groups: people 65 and older, adults at high risk of severe COVID-19, and adults whose frequent occupational or institutional exposure places them at high risk of serious complications.

FDA’s action was narrower than Pfizer’s original request to make boosters available to everyone 16 and older, but broader than the most restrictive interpretation of last week’s advisory-panel vote. It reflects regulators’ judgment that the evidence of benefit is strongest for older and vulnerable adults while allowing exposure risk to matter in selected working-age populations.

The booster remains the same 30-microgram Pfizer dose used in the original series and is authorized only after at least six months. People vaccinated with Moderna or Johnson & Johnson are not included in this week’s decision; regulators are awaiting additional data on those products.

Pfizer’s own September 17 statement highlighted increased antibody levels after a third dose and real-world evidence from Israel, where boosters were deployed earlier as protection against infection appeared to wane.

ACIP drew sharper lines around age and medical risk

During meetings Wednesday and Thursday, ACIP reviewed U.S. vaccine-effectiveness data, safety monitoring, Pfizer’s clinical results and modeling of booster benefits. Its archived presentation materials show the committee grappling with a central distinction: protection against infection has declined more than protection against hospitalization and death.

The committee voted 15-0 to recommend boosters for people 65 and older and long-term-care residents. It voted 13-2 for adults 50 to 64 with underlying medical conditions and 9-6 to allow adults 18 to 49 with medical conditions to choose a booster based on individual risk.

But ACIP voted 9-6 against recommending boosters solely because of occupational or institutional exposure. Members who opposed that category argued that protection against severe disease remains strong for most younger adults and worried that an expansive recommendation could blur the distinction between clinical need and exposure risk.

The committee’s detailed evidence framework weighed potential prevention of infections and hospitalizations against uncertainties about the duration of added protection and uncommon adverse events. A separate benefit-risk presentation examined how age and underlying illness change the expected value of an additional dose.

Walensky’s occupational-risk decision expands access

CDC directors generally accept ACIP recommendations, but they have authority to modify them. Walensky accepted the panel’s age and medical-risk recommendations while declining to adopt its negative vote on occupational exposure.

The practical effect is significant. Healthcare employees, school staff and other workers who interact with large numbers of people can now receive boosters if they completed a Pfizer series at least six months ago. The decision is permissive rather than mandatory: eligible workers “may” receive a dose after considering their circumstances.

The CDC’s clinical-considerations presentation emphasized that providers should consider age, medical conditions, occupational exposure, local transmission and the interval since vaccination. The framework acknowledges that risk is not uniform across the newly eligible population.

Coverage will not be a financial barrier for most patients. The Centers for Medicare & Medicaid Services said Friday that boosters will be covered without cost sharing under Medicare and, in most circumstances, Medicaid, CHIP and commercial insurance.

The policy is targeted, but the booster debate is not over

The new recommendations arrive amid evidence that Delta has increased breakthrough infections while vaccines continue to provide substantial protection from severe outcomes. Older adults vaccinated early in the rollout have shown the clearest signs of declining protection against hospitalization, strengthening the case for boosters in that population.

For younger adults, the evidence is more complicated. A third dose raises antibody levels, but the absolute risk of hospitalization after two doses remains low for many healthy people. Regulators must also monitor rare myocarditis, particularly among younger males, as booster use expands.

Pfizer presented updated safety and immunogenicity data to ACIP in a September 22 briefing, while CDC investigators reviewed early safety reports from third doses already given to immunocompromised patients. So far, the reported pattern of common reactions resembles that seen after the second dose, but the booster population remains much smaller.

The policy could broaden again as more evidence arrives. FDA and CDC still must evaluate boosters for Moderna and Johnson & Johnson recipients, and they may revisit eligibility as protection changes over time. For now, the United States has moved from planning a universal adult booster campaign to a more targeted approach centered on age, medical vulnerability and exposure risk.